Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-COVID-2019 monoclonal antibody - Ology Bioservices

Drug Profile

Anti-COVID-2019 monoclonal antibody - Ology Bioservices

Latest Information Update: 01 Apr 2020

At a glance

  • Originator Vanderbilt University Medical Center
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 27 Mar 2020 Twist Bioscience entered into collaboration agreement with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19
  • 23 Mar 2020 Vanderbilt University Medical Center and Ology Bioservices agree to develop and manufacture monoclonal antibody for COVID-2019 infections
  • 23 Mar 2020 Early research in COVID-2019 infections (Prevention) in USA (Parenteral)

Development Overview

Introduction

Human monoclonal antibody for the treatment and prevention of COVID-2019 infections is being developed by Ology Bioservices in collaboration with Vanderbilt University Medical Center (VUMC) under the Pandemic Prevention Platform (P3) network of the U.S. Defense Advanced Research Projects Agency (DARPA). Early research is underway in the US.

Company Agreements

In March 2020, Twist Bioscience Corporation entered into a collaboration agreement with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19. Twist Biopharma will provide custom antibody drug discovery libraries and will screen the libraries for potential antibody therapeutics that would treat patients with COVID-19. [1]

Prior to March 2020, Ology Bioservices and Vanderbilt University Medical Center (VUMC) entered into an agreement to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus. The aim of the program is to rapidly and efficiently deliver the antibody to the Department of Defense. Under the proposed terms of the pending agreement with VUMC, researchers in the Vanderbilt Vaccine Center (VVC) will be tasked in this program with rapid antibody discovery efforts as a performance site for the Pandemic Prevention Platform (P3) network of the U.S. Defense Advanced Research Projects Agency (DARPA). [2]

Key Development Milestones

Financing information

In March 2020, the Department of Defense (DOD) awarded a contract valued at $US14 million with Ology Bioservices to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus. The work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency. Under this program, Ology Bioservices will work with Vanderbilt University Medical Center (VUMC) to develop and manufacture the monoclonal antibody. The aim of the program is to rapidly and efficiently deliver the antibody to the Department of Defense [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research USA Parenteral / unspecified Vanderbilt University Medical Center 23 Mar 2020
COVID 2019 infections - Prevention Research USA Parenteral / unspecified Vanderbilt University Medical Center 23 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Vanderbilt University Medical Center Originator USA
Vanderbilt University Medical Center Owner USA
Department of defence Funder USA
Twist Bioscience Collaborator USA
Ology Bioservices Collaborator USA

Development History

Event Date Update Type Comment
27 Mar 2020 Licensing Status Twist Bioscience entered into collaboration agreement with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19 [1] Updated 01 Apr 2020
23 Mar 2020 Licensing Status Vanderbilt University Medical Center and Ology Bioservices agree to develop and manufacture monoclonal antibody for COVID-2019 infections [2] Updated 01 Apr 2020
23 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in USA (Parenteral) [2] Updated 01 Apr 2020
23 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (Parenteral) [2] Updated 01 Apr 2020

References

  1. Twist Bioscience Partners with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19.

    Media Release
  2. Ology Bioservices, Vanderbilt University Medical Center to Develop, Manufacture Monoconal Antibody for Treatment, Prevention of Infection With COVID-19 Virus for Department of Defense.

    Media Release
Back to top